BioMarin Pharmaceutical Inc expected to post earnings of 62 cents a share - Earnings Preview
BioMarin Pharmaceutical Inc is expected to report earnings of 62 cents per share. This earnings preview is based on information from Refinitiv dated February 2026. The article is a brief financial news piece indicating the company's anticipated performance.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has received a "Moderate Buy" consensus rating from 25 analysts, with an average 12-month price target of $88.29. The stock opened at $59.95, and institutional ownership stands at approximately 98.71%. Recent analyst reports show mixed views, with some upgrades and price target increases, while others cut price targets or downgraded the stock.
BioMarin Pharmaceutical (Nasdaq:BMRN) - Stock Analysis
This Simply Wall St analysis of BioMarin Pharmaceutical (BMRN) provides an overview of the biotechnology company, highlighting its current stock performance, valuation, and future growth prospects. The report notes BMRN is trading below its fair value, with earnings projected to grow by 18.09% annually, and details recent company updates and competitive landscape.
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
BioMarin Pharmaceutical Inc. announced it will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m. ET. The call will discuss the company's fourth quarter and full-year 2025 financial results and provide a business update. Alexander Hardy, President and CEO, will host the event, which will be accessible via dial-in numbers and a live audio webcast on BioMarin's investor website.
What Makes BioMarin (BMRN) so Attractive
BioMarin Pharmaceutical (BMRN) is highlighted as an attractive biotechnology stock with significant upside potential, based on analyst sentiment and price targets. Piper Sandler reiterated an Overweight rating despite a reduced price target, still implying over 40% upside. The company specializes in therapies for rare genetic diseases and has a strong product pipeline.
Aberdeen Group plc Sells 80,297 Shares of BioMarin Pharmaceutical Inc. $BMRN
Aberdeen Group plc reduced its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 8.2% in the third quarter, selling 80,297 shares and retaining 902,751 shares valued at $48.89 million. Other institutional investors like NewEdge Advisors LLC and Empowered Funds LLC increased their holdings in BioMarin during recent quarters. The article also provides BioMarin Pharmaceutical's current stock performance, market capitalization, P/E ratio, and recent analyst price targets and ratings.
LSV Asset Management Purchases 812,284 Shares of BioMarin Pharmaceutical Inc. $BMRN
LSV Asset Management significantly increased its stake in BioMarin Pharmaceutical Inc. in the third quarter, purchasing an additional 812,284 shares to own a total of 845,500 shares valued at approximately $45.79 million. Hedge funds and other institutional investors own a substantial 98.71% of BioMarin's stock. Wall Street analysts currently rate BioMarin as a "Moderate Buy" with a consensus target price of $88.29, significantly higher than its recent trading price around $59.87.
New York Life Investment Management LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN
New York Life Investment Management LLC has initiated a new investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by acquiring 19,783 shares valued at approximately $1.07 million in the third quarter. Several other institutional investors also adjusted their positions in BioMarin, which maintains a "Moderate Buy" consensus rating from analysts with an average target price of $88.29. The biopharmaceutical company specializes in therapies for rare genetic and metabolic diseases, with 98.71% institutional ownership of its stock.
Assessing BioMarin Pharmaceutical (BMRN) Valuation After Mixed Short And Long Term Share Price Performance
BioMarin Pharmaceutical (BMRN) has shown mixed share price performance, with recent short-term gains contrasting with a yearly decline. Despite this, the company appears undervalued, with a fair value estimated around $90.74 against its current price of $59.87, driven by strong revenue growth and pipeline advancements. While its P/E ratio aligns with the biotech industry average, potential risks like increased R&D spending or pricing pressures could impact future margins.
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company
BioMarin has entered into an Indenture with U.S. Bank Trust Company to issue $850 million in 5.500% Senior Notes. These privately placed notes will fund the pending acquisition of Amicus Therapeutics and related costs, alongside new term loan facilities and existing cash. The notes are guaranteed by BioMarin subsidiaries and include standard covenants.
BioMarin finances Amicus acquisition with $850M notes and new loans
BioMarin has finalized an $850 million private offering of 5.500% senior unsecured notes due 2034 to help fund its pending acquisition of Amicus. This offering, along with new Term Loan A and B facilities and a proposed revolving credit facility, forms a comprehensive debt package for the acquisition. The proceeds are held in escrow and will be mandatorily redeemed if the acquisition is not completed by December 19, 2026.
BioMarin Announces Closing of Private Offering of Senior Notes
BioMarin Pharmaceutical Inc. has announced the closing of its private offering of $850 million of 5.500% senior unsecured notes due 2034. The proceeds, along with new senior secured term loan facilities and cash, will fund the acquisition of Amicus Therapeutics, Inc. The notes are subject to mandatory redemption if the acquisition is not completed by December 19, 2026, or if certain other events occur.
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC
The US Federal Trade Commission has granted early termination to BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of Amicus Therapeutics, effectively approving the deal. This fast-tracks the acquisition, as the Hart-Scott-Rodino Act waiting period was originally set to expire on February 20, 2026, but the companies received the green light on February 11, 2026. The transaction is anticipated to close in the second quarter of 2026.
Baird maintains BioMarin stock rating amid competitor’s positive trial data
Baird has reiterated its Neutral rating and $65.00 price target for BioMarin Pharmaceutical Inc. despite positive clinical trial results from competitor BridgeBio for its achondroplasia treatment. BioMarin's Voxzogo faces potential competition from BridgeBio's oral treatment, but Baird noted that infigratinib's label would likely be restricted to older patients, limiting its competitive impact. BioMarin also recently announced an $850 million issuance of senior unsecured notes and the syndication of a $2 billion senior secured term loan to finance its acquisition of Amicus Therapeutics, with Canaccord Genuity upgrading its rating to Buy based on this acquisition.
Is BioMarin Pharmaceutical (BMRN) Now Trading Below Its Long Term Prospects
BioMarin Pharmaceutical (BMRN) appears undervalued based on a Discounted Cash Flow (DCF) analysis, which suggests its shares are trading approximately 46.2% below their estimated intrinsic value. While its P/E ratio is close to the biotech industry average, a proprietary "Fair Ratio" also indicates a modest discount. The company's recent performance shows a decline over 1, 3, and 5 years, with current attention focused on its rare disease drug portfolio and regulatory developments.
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
BioMarin Pharmaceutical (BMRN) is projected to report a year-over-year decline in earnings for Q4 2025, despite an expected increase in revenues. The consensus EPS estimate is $0.25 per share, down 72.8%, with revenues estimated at $829.66 million, up 11%. Despite a positive track record of beating EPS estimates in the past four quarters, the current Zacks Earnings ESP and Rank suggest it's difficult to conclusively predict an earnings beat for BioMarin this quarter.
BioMarin Pharmaceutical Stock Outlook Looks Promising
BioMarin Pharmaceutical (BMRN) shows a promising outlook according to recent analyst ratings and upcoming catalysts. Several firms, including Piper Sandler, Barclays, and Canaccord Genuity, have issued positive ratings and price targets, citing potential tailwinds in the biotech sector and the impact of the pending acquisition of Amicus Therapeutics. The company's focus on rare disease therapies and its product pipeline further contribute to the optimistic sentiment.
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)?
BioMarin Pharmaceutical Inc. (BMRN) has received revised price targets and rating updates from several financial firms. Piper Sandler maintained an Overweight rating but lowered its price target to $84, while Barclays initiated coverage with an Overweight rating and an $80 price target, citing optimistic biotech industry outlooks for 2026. Canaccord Genuity upgraded BMRN to Buy, increasing its price target to $84 on the expectation that the acquisition of Amicus will be a key catalyst for the stock.
BioMarin’s Strategic Acquisition Nears Critical Data Readout
BioMarin Pharmaceutical is nearing a critical data readout for its experimental therapy INZ-701, acquired through its 2025 acquisition of Inozyme Pharma. The drug aims to treat ENPP1 Deficiency, a severe genetic condition. Positive results from the upcoming ENERGY-3 study are crucial for regulatory submission and could solidify BioMarin's position in the rare disease market.
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)?
BioMarin Pharmaceutical Inc. (BMRN) has received optimistic ratings and price target revisions from several analyst firms. Piper Sandler maintained an Overweight rating with a revised price target of $84, while Barclays initiated coverage with an Overweight rating and an $80 price target, citing significant tailwinds for the biotech industry in 2026. Canaccord Genuity upgraded BMRN to Buy, adjusting the price target to $84, and believes the pending acquisition of Amicus will be a key catalyst for the stock.
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum
BioMarin Pharmaceutical (BMRN) has seen recent share price momentum with a 13.0% return over the past three months, contrasting with a 9.1% decline over the last year. Analysts believe the company is 35.9% undervalued, with a fair value of $90.74 against its current $58.13 share price, based on expected annual revenue growth of 7.6% and an increase in profit margins from 21.5% to 29.8% over the next three years. However, the valuation carries execution risks related to R&D, SG&A spending, and pricing in the rare disease market.
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays
Barclays has initiated coverage of BioMarin Pharmaceutical (BMRN) with an "Overweight" rating and an $80 target price, citing the company's acquisition plans and strong fundamentals. The firm notes BioMarin's finalized $2 billion senior secured term loan B, which along with other financing, will fund a planned acquisition, possibly Amicus Therapeutics. Analysts generally have a "Buy" rating on BMRN, with a median target price of $96.50.
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN
Callan Family Office LLC has reduced its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 37.5%, now holding 41,891 shares valued at $2.27 million. Despite this reduction, institutional investors collectively own 98.71% of the company's stock. Analysts currently rate BioMarin as a "Moderate Buy" with an average price target of $90.04.
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN
AlphaQuest LLC significantly reduced its stake in BioMarin Pharmaceutical Inc. by 61.7% in Q3, selling 21,696 shares and retaining 13,460 shares valued at approximately $729,000. Despite this sell-off, institutional ownership of BMRN remains very high at 98.71%, with several other funds recently increasing their positions. Wall Street analysts maintain a "Moderate Buy" consensus rating for BioMarin, with an average price target of $90.04 against a recent share price of $57.61.
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia
BioMarin Pharmaceutical Inc. is set to acquire Amicus Therapeutics for $4.8 billion. Amicus Therapeutics, a rare-disease company with operations in Philadelphia, specializes in therapies for genetic disorders. This acquisition will expand BioMarin's portfolio in the rare disease therapeutic area.
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc.
Federated Hermes Inc. significantly increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 292.6% in the third quarter, acquiring an additional 207,430 shares. This purchase brings their total holdings to 278,315 shares, valued at approximately $15.07 million. Institutional ownership of BioMarin is notably high at 98.71%, with other major holders including Dodge & Cox, Viking Global, AQR Capital Management, Geode Capital Management, and Norges Bank.
Should You Buy BioMarin Pharmaceutical Before Feb. 18?
BioMarin Pharmaceutical is expected to report its Q4 2025 results around February 18, 2026, with strong anticipated sales for its rare-disease drug, Voxzogo, and several upcoming catalysts like PDUFA dates and clinical trial results. However, potential competition for Voxzogo and the timing of ex-U.S. orders introduce uncertainty, suggesting investors may not need to rush into buying the stock despite a pending acquisition set to boost growth.
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. announced the pricing of an $850 million offering of 5.500% senior unsecured notes due 2034 and the completion of syndication for a new $2.0 billion senior secured term loan "B" facility. These financial arrangements, alongside an $800 million Term Loan A and a $600 million revolving credit facility, are intended to fund the pending acquisition of Amicus Therapeutics, Inc. The notes proceeds will be held in escrow and are subject to special mandatory redemption if the acquisition is not completed by December 19, 2026.
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication
BioMarin Pharmaceutical Inc. announced the pricing of $850 million in senior notes due 2034 with a 5.500% interest rate and completed the syndication of a $2 billion senior secured term loan B facility. These funds are intended to finance the acquisition of Amicus Therapeutics, Inc., with the note offering expected to close by February 12, 2026. The proceeds will cover acquisition costs and related expenses.
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. has announced the pricing of a $850 million private offering of 5.500% senior unsecured notes due 2034, which is expected to close on February 12, 2026. Concurrently, the company completed the syndication of a new $2 billion senior secured term loan "B" facility, in connection with its pending acquisition of Amicus Therapeutics, Inc. The proceeds from these offerings, along with cash on hand, will be used to fund the acquisition, related fees, and expenses.
Assessing BioMarin Pharmaceutical (BMRN) Valuation As Investors Revisit The Rare Disease Specialist
BioMarin Pharmaceutical (BMRN) valuation is being reassessed by investors as its share price has shown recent swings, with analysts suggesting it is significantly undervalued at $56.78 against a fair value of $89.74. The company's strong year-over-year revenue growth, driven by key therapies like VOXZOGO and VIMIZIM, supports this optimistic outlook, though potential competition and rising R&D/SG&A costs could impact future margins. Investors are optimistic about compounding revenue, rising margins, and potential for richer future earnings.
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN)
Analysts are maintaining a bullish stance on BioMarin Pharmaceutical (BMRN) due to its encouraging fundamentals and the anticipated acquisition of Amicus Therapeutics. Canaccord Genuity and Truist Securities have both raised their price targets for BMRN, citing the strategic alignment of the acquisition with BioMarin's drug portfolio and rare disease focus. The acquisition is expected to finalize in Q2 2026 and become accretive within 12 months.
Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis
BioMarin Pharmaceutical Inc. (BMRN) is highlighted as a promising investment due to strong analyst ratings and the company's commitment to double-digit revenue growth into the 2030s. Analysts from Canaccord Genuity and Wedbush have raised price targets and reaffirmed Buy ratings, citing the success of Voxzogo, pipeline advancements, and strategic efforts to protect market position. The article emphasizes BMRN's leadership in therapies for rare diseases and potential for long-term growth.
BioMarin lines up $2B loan, $800M facility for Amicus deal
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a proposed private offering of $850 million senior unsecured notes due 2034 and launched syndication for new senior secured credit facilities totaling $3.4 billion ($2 billion Term Loan B, $800 million Term Loan A, and $600 million revolving facility). These funds, along with cash on hand, are intended to finance its pending acquisition of Amicus Therapeutics, Inc. The notes proceeds will be held in escrow and are subject to mandatory redemption if the acquisition is not completed by December 19, 2026.
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
BioMarin Pharmaceutical Inc. announced a proposed private offering of $850 million senior unsecured notes due 2034 and launched the syndication of a new $2 billion senior secured term loan "B" facility. These financial maneuvers are primarily intended to fund the pending acquisition of Amicus Therapeutics, Inc., along with covering related fees and expenses. The offering of the Notes is subject to specific conditions, including a mandatory redemption clause if the acquisition is not completed by December 19, 2026.
Y Intercept Hong Kong Ltd Sells 51,159 Shares of BioMarin Pharmaceutical Inc. $BMRN
Y Intercept Hong Kong Ltd decreased its stake in BioMarin Pharmaceutical Inc. by selling 51,159 shares, reducing its holdings to 90,509 shares valued at $4.90 million. Despite mixed Q3 results, institutional ownership of BioMarin remains high at 98.71%, with several other major funds increasing their positions. Analysts currently have an average "Moderate Buy" rating for BioMarin, with a consensus target price of $90.04.
Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. $BMRN
Sector Gamma AS increased its stake in BioMarin Pharmaceutical (NASDAQ: BMRN) by 43.7% in Q3, now holding 175,852 shares valued at approximately $9.52 million. This makes BioMarin its 13th largest holding, representing about 2.4% of its portfolio. Despite missing Q3 earnings and revenue estimates, BioMarin provided a strong FY2025 EPS guidance, and analysts maintain a "Moderate Buy" rating with an average target price of $90.04.
Rakuten Investment Management Inc. Acquires New Shares in BioMarin Pharmaceutical Inc. $BMRN
Rakuten Investment Management Inc. has acquired 23,358 shares of BioMarin Pharmaceutical (NASDAQ: BMRN), valued at approximately $1.265 million, increasing institutional ownership to 98.71%. This comes despite BioMarin missing Q3 EPS and revenue estimates, though the company provided positive FY2025 EPS guidance. Wall Street maintains a "Moderate Buy" rating with an average target price of $90.04 for the biotechnology firm.
BioMarin Pharmaceutical Is Quietly Exploding — Is BMRN the Biotech Stock You’re Sleeping On?
BioMarin Pharmaceutical (BMRN) is gaining attention in the biotech sector for its focus on rare genetic diseases, which allows for high drug prices and significant revenue potential. The company's business model leverages specialized treatments for conditions with limited options, and its pipeline includes approved drugs and promising late-stage candidates, including gene therapies. While BioMarin presents significant upside due to its concentrated focus and innovative therapies, it also carries high clinical and regulatory risks, making it a high-stakes, catalyst-driven investment suitable for investors with a strong risk tolerance and willingness to track market developments closely.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) has been identified as a compelling value investment opportunity, showing strong financial health, profitability, and growth prospects. The company's valuation metrics suggest it is undervalued compared to its biotechnology industry peers, offering a potential margin of safety for investors. This assessment is based on its good valuation rating, solid balance sheet, high-quality margins, and positive revenue and EPS growth.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have issued an average "Moderate Buy" recommendation for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with a consensus 12-month price target of $90.04. This rating comes despite the company missing Q3 EPS estimates, though it provided a positive FY 2025 EPS guidance. Institutional ownership of the stock is high, with major investors increasing their stakes recently.
BioMarin vets form Mendra to ‘modernize’ rare disease drug development
Mendra, a new startup founded by former BioMarin and Escient Pharmaceuticals executives, has launched with $82 million in Series A funding. The company plans to acquire rare disease assets and leverage artificial intelligence to accelerate drug development, including patient identification, clinical trial enrollment, and commercialization planning. This initiative aims to modernize and streamline the challenging process of bringing rare disease therapies to market.
Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D
Former BioMarin executives have launched Mendra, a new biotechnology company focused on accelerating rare disease drug development by leveraging existing assets. The company secured $82 million in Series A financing and aims to modernize R&D by in-licensing late-stage experimental therapies and deploying advanced analytics. Mendra plans to advance its lead program for a rare metabolic disease within the next year.
Campbell & CO Investment Adviser LLC Trims Stake in BioMarin Pharmaceutical Inc. $BMRN
Campbell & CO Investment Adviser LLC significantly reduced its stake in BioMarin Pharmaceutical Inc. by 75.6% during the third quarter, ending with 18,213 shares valued at $986,000. Despite this, BioMarin Pharmaceutical (NASDAQ:BMRN) maintains a consensus "Moderate Buy" rating from analysts with a target price of $89.70, even after missing its Q3 earnings estimates. The biotechnology company, specializing in rare genetic diseases, has set FY2025 guidance at 3.500-3.600 EPS, while its stock currently trades around $54.59.
Is BioMarin (BMRN) Elevating Digital Strategy To Sharpen Its Innovation And Efficiency Edge?
BioMarin Pharmaceutical Inc. has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new role aimed at enhancing the company's digital strategy and data-driven decision-making. This move is expected to influence BioMarin's investment narrative by focusing on innovation and efficiency, particularly as the company faces a crucial FDA decision for its PALYNZIQ treatment and manages rising R&D and SG&A costs. Analysts forecast significant revenue and earnings growth by 2028, with a fair value estimate suggesting substantial upside potential.
Korea’s Ildong promotes Chae Joon Lee to co-CEO
Ildong Pharmaceutical Co. Ltd. has promoted Chae Joon Lee to co-CEO from COO, where he will also continue as president and serve key roles in Ildong affiliates. Additionally, BioMarin Pharmaceutical Inc. has appointed Arpit Davé as its first EVP and chief digital and information officer, tasked with leading the company's enterprise technology strategy and digital transformation. Davé joins BioMarin from Amgen Inc.
BioMarin drops development of liver, lung disease asset
BioMarin Pharmaceutical has decided to discontinue the development of BMN 331, an investigational therapy for Alpha-1 antitrypsin deficiency (AATD) related liver and lung disease. This decision follows preclinical findings that indicated the therapy would not provide substantial clinical benefits, leading the company to reallocate resources to other promising programs.
BioMarin drops development of liver, lung disease asset
BioMarin Pharmaceutical has announced it will discontinue the development of BMN 331, an investigational gene therapy for alpha-1 antitrypsin deficiency (AATD), due to safety concerns observed in an early-stage clinical trial. The company stated that the safety profile was not competitive enough to advance the program, leading to a strategic decision to focus on other pipeline assets. This decision follows previous announcements of BMN 331's early clinical trial results.
BioMarin names Arpit Davé as Chief Digital and Information Officer
BioMarin Pharmaceutical Inc. has appointed Indian American executive Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a newly created role. Davé will be responsible for the company's enterprise technology strategy, data science, and digital transformation, bringing over 20 years of experience in information technology and AI from companies like Amgen, Bristol Myers Squibb, and Merck. This appointment aims to leverage technology and AI to enhance BioMarin's business operations and accelerate the delivery of life-changing therapies.
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference
BioMarin Pharmaceutical presented its strategic priorities and preliminary 2025 revenue figures at the J.P. Morgan Healthcare Conference, targeting significant growth driven by Voxzogo, its enzyme therapies, and the pending acquisition of Amicus. The company announced estimated 2025 revenue of $3.2 billion, with Voxzogo's performance particularly strong at $920 million. BioMarin also outlined upcoming regulatory and clinical catalysts for its pipeline, including a full approval filing for Voxzogo and advancements for BMN 351 and BMN 333.
